Search Results
Search for other papers by Chantal A Lebbink in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Agnieszka Czarniecka in
Google Scholar
PubMed
Search for other papers by Renuka P Dias in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Louise Izatt in
Google Scholar
PubMed
Search for other papers by Heiko Krude in
Google Scholar
PubMed
Search for other papers by Kerstin Lorenz in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Arnoldo Piccardo in
Google Scholar
PubMed
Search for other papers by Manuel Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by Toru Takano in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
et al. reported three cases for whom lenvatinib was given ( 119 ). Two patients remained clinically stable on lenvatinib 11 and 23 months after initiation of therapy. The third patient transitioned to a tumor-specific targeted therapy after 1 month